{'fraction_non_alphanumeric': 0.021686746987951807, 'fraction_numerical': 0.00321285140562249, 'mean_word_length': 5.960893854748603, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Coacervate delivery of HB‐EGF accelerates healing of type 2 diabetic wounds

Chronic wounds such as diabetic ulcers pose a significant challenge as a number of underlying deficiencies prevent natural healing. In pursuit of a regenerative wound therapy, we developed a heparin‐based coacervate delivery system that provides controlled release of heparin‐binding epidermal growth factor (EGF)‐like growth factor (HB‐EGF) within the wound bed. In this study, we used a polygenic type 2 diabetic mouse model to evaluate the capacity of HB‐EGF coacervate to overcome the deficiencies of diabetic wound healing. In full‐thickness excisional wounds on NONcNZO10 diabetic mice, HB‐EGF coacervate enhanced the proliferation and migration of epidermal keratinocytes, leading to accelerated epithelialization. Furthermore, increased collagen deposition within the wound bed led to faster wound contraction and greater wound vascularization. Additionally, in vitro assays demonstrated that HB‐EGF released from the coacervate successfully increased migration of diabetic human keratinocytes. The multifunctional role of HB‐EGF in the healing process and its enhanced efficacy when delivered by the coacervate make it a promising therapy for diabetic wounds.